DoubleIdat.i
Curation
Accueil
Racine
Curation
Exploration
Accueil
Racine
Accueil
Racine

La maladie de Parkinson au Canada (serveur d'exploration) - Curation (Accueil)

Index « DoubleIdat.i » - tête de navigation
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Index : DoubleIdat.i

Pour accéder à une entrée :

Les termes de plus forte occurence

18756-7938:2008:Baghbaderani B:expansion:of:human
18756-3282:2012:Dennison E:effect:of:co
11748-6645:2013:Davidson P:source:memory:in
11748-6645:2013:Christopher L:neuroimaging:of:brain
11615-9306:2005:Wady L:methyl:benzoate:as
11552-4825:2009:Zaleski C:the:co:occurrence
11543-3633:2005:Perretta J:effects:of:parkinson
11530-7026:2003:Pell M:processing:emotional:tone
11471-003X:2011:Neuwelt E:engaging:neuroscience:to
11420-8008:2005:Wiltshire K:corpus:callosum:in
11388-2457:2007:Stemmer B:the:error:negativity
11388-2457:2007:Fawcett A:saccade:related:potentials
11388-2457:2005:Duval C:the:impact:of
11388-2457:2004:Hanajima R:somatosensory:evoked:potentials
11388-2457:2003:Wennberg R:intracranial:volume:conduction
11388-2457:2002:Tremblay F:cortico:motor:excitability
11388-2457:2001:Chen R:impairment:of:motor
11388-2457:2001:Ashby P:potentials:recorded:at
11381-6128:2005:Hayley S:multiple:mechanisms:of
11381-6128:2000:Cyr M:drugs:with:estrogen
11380-3395:2006:Burton C:intraindividual:variability:as
11380-3395:2002:Kingstone A:orienting:attention:in
11368-5031:2008:Poewe W:diagnosis:and:management
11359-6446:1998:Samii A:prospects:for:new
11355-6037:1998:Jaeggi E:ventriculo:atrial:time
11353-8020:2001:Rajput A:levodopa:prolongs:life
11353-8020:2001:Pal P:positron:emission:tomography
11353-8020:1996:Calne S:validating:a:quality
11352-4585:2003:Mcdonnell G:clinical:presentation:of
11351-0711:2013:Harris M:head:injuries:and
11172-7047:2007:Mcgeer E:the:role:of
11170-7690:2006:Willan A:economic:evaluation:of
11170-7690:2003:Iskedjian M:cost:analysis:of
11079-5006:1999:Mitnitski A:the:rate:of
11065-9471:2010:Ng B:focusing:effects:of
11065-9471:2009:Ballanger B:cerebral:blood:flow
11059-910X:2010:Hermo L:surfing:the:wave
11045-3873:2000:Barlow M:unipolar:electrogram:characteristics
11045-3873:1994:Li H:fatigue:phenomenon:in
11041-6102:2006:Vida S:an:month:prospective
11041-6102:2005:Hagen B:antipsychotic:drug:use
11034-4810:1991:Rosenberg H:near:miss:sudden
11021-7762:1998:Le Dorze G:a:comparison:of
11011-6125:2016:Hamani C:pedunculopontine:nucleus:region
11011-6125:2002:Westerberg B:the:effects:of
11011-6125:1998:Lozano A:microelectrode:recordings:define
11011-6125:1998:Ashby P:immediate:motor:effects
11010-7940:1988:Guiraudon G:surgical:approach:to
10964-6906:2011:Ross O:ataxin:repeat:length
10964-6906:2010:Kanao T:activation:of:foxo
10964-6906:2010:Irrcher I:loss:of:the
10964-6906:2009:Venderova K:leucine:rich:repeat
10964-6906:2009:Cronin K:expansion:of:the
10962-1083:2000:Mccusker M:mitochondrial:dna:variation
10960-0760:2003:Bhavnani B:estrogens:and:menopause
10959-4965:2011:Weinberger M:a:basis:for
10959-4965:2004:Frak V:a:dissociation:between
10959-4965:2003:Strafella A:subthalamic:deep:brain
10959-4965:1997:Newman D:a:kappa:opioid
10959-4965:1995:Chagnon P:distribution:of:brain
10959-4965:1994:Hutchison W:differential:neuronal:activity
10959-4965:1994:Figlewicz D:the:cu:zn
10959-4965:1994:Asselin M:striatal:changes:in
10959-4388:1998:Lozano A:new:developments:in
10953-8194:2012:Al Sweidi S:oestrogen:receptors:and
10953-816X:2013:Sutton A:elevated:potassium:provides
10953-816X:2013:Huot P:use:of:catechol
10953-816X:2001:Metz G:chronic:levodopa:therapy
10936-3076:1994:Hammerstad J:tendon:jerks:in
10929-1393:1998:Mclean M:impacts:of:the
10926-6410:2005:Pell M:facial:expression:decoding
10920-9964:2005:Chouinard G:manual:for:the
10895-4356:2003:Coyle D:measures:of:importance
10895-4356:1994:Wang F:reliability:of:environmental
10895-4356:1994:Fu Lin Wang:reliability:of:environmental
10895-4356:1992:Wang F:an:assessment:of
10894-878X:1997:Freedman M:breakdown:of:cross
10894-4105:2013:Foster E:prospective:memory:in
10894-4105:2005:Gilbert B:study:of:verbal
10894-4105:1998:West R:the:contribution:of
10894-1491:2005:Klegeris A:chymotrypsin:like:proteases
10893-6080:2000:Monchi O:a:neural:model
10893-0341:1998:Mcgeer P:glial:cell:reactions
10891-9887:2012:Matteau E:clinical:validity:of
10891-9887:1997:Mamelak M:neurodegeneration:sleep:and
10891-9887:1993:Rajput A:alzheimer:s:disease
10891-5849:1999:Ste Marie L:local:striatal:infusion
10890-6238:1991:Levy M:fetal:outcome:following
10887-8994:1994:Sloane A:neuronal:intranuclear:hyaline
10887-6177:2008:Fraraccio M:absence:of:cognitive
10887-4476:2008:Seeman P:dopamine:d:high
10885-6230:2007:Voon V:antidepressants:and:psychosis
10885-3185:2012:Vendette M:brain:perfusion:anomalies
10885-3185:2012:Stern M:toward:a:redefinition
10885-3185:2012:Siderowf A:premotor:parkinson:s
10885-3185:2012:Romenets S:rapid:eye:movement
10885-3185:2012:Reginold W:the:pill:questionnaire
10885-3185:2012:Ray N:the:neurobiology:and
10885-3185:2012:Ravina B:dopamine:transporter:imaging
10885-3185:2012:Postuma R:rapid:eye:movement
10885-3185:2012:Postuma R:identifying:prodromal:parkinson
10885-3185:2012:Pifl C:thalamic:noradrenaline:in
10885-3185:2012:Lees A:perampanel:an:ampa
10885-3185:2012:Huot P:increased:levels:of
10885-3185:2012:Harris M:association:of:parkinson
10885-3185:2012:Goldman S:genetic:modification:of
10885-3185:2012:Godau J:neuroimaging:current:role
10885-3185:2012:Fox S:a:critique:of
10885-3185:2012:Dubois B:donepezil:in:parkinson
10885-3185:2012:De Cock V:suggested:immobilization:test
10885-3185:2012:Buchman A:locus:coeruleus:neuron
10885-3185:2012:Bertrand J:color:discrimination:deficits
10885-3185:2011:Vendette M:brain:perfusion:and
10885-3185:2011:Van Lieshout P:tongue:control:for
10885-3185:2011:Stoessl A:milestones:in:neuroimaging
10885-3185:2011:Seppi K:the:movement:disorder
10885-3185:2011:Sampaio C:pardoprunox:in:early
10885-3185:2011:Ross O:genetic:variants:of
10885-3185:2011:Rascol O:milestones:in:parkinson
10885-3185:2011:Postuma R:cardiac:autonomic:denervation
10885-3185:2011:Ponce F:the:most:cited
10885-3185:2011:Marras C:predictors:of:time
10885-3185:2011:Lang A:a:critical:appraisal
10885-3185:2011:Kupsch A:early:postoperative:management
10885-3185:2011:Koprich J:the:selective:mu
10885-3185:2011:Klein C:the:curious:case
10885-3185:2011:Kimmelman J:risk:of:surgical
10885-3185:2011:Heldman D:the:modified:bradykinesia
10885-3185:2011:Goldman J:racial:differences:may
10885-3185:2011:Fox S:the:movement:disorder
10885-3185:2011:Espay A:differential:response:of
10885-3185:2011:Cilia R:pathological:gambling:in
10885-3185:2011:Camicioli R:ventricular:dilatation:and
10885-3185:2011:Berg D:afq:treatment:of
10885-3185:2011:Altman R:caffeine:in:parkinson
10885-3185:2010:Yeh I:somatosensory:evoked:potentials
10885-3185:2010:Vitek J:standard:guidelines:for
10885-3185:2010:Sossi V:dopamine:turnover:increases
10885-3185:2010:Sage M:a:positive:influence
10885-3185:2010:Roland K:an:exploration:of
10885-3185:2010:Postuma R:cardiac:autonomic:dysfunction
10885-3185:2010:Okun M:reply:based:on
10885-3185:2010:Moro E:long:term:results
10885-3185:2010:Lozano A:basal:ganglia:physiology
10885-3185:2010:Lim S:the:nonmotor:symptoms
10885-3185:2010:Johnston T:effect:of:histamine
10885-3185:2010:Gagnon J:the:montreal:cognitive
10885-3185:2010:Evans A:compulsive:use:of
10885-3185:2010:Espay A:early:versus:delayed
10885-3185:2010:Elble R:impact:of:belief
10885-3185:2010:Colosimo C:task:force:report
10885-3185:2010:Chou K:a:recommended:scale
10885-3185:2010:Callaghan R:incidence:of:parkinson
10885-3185:2010:Bronzova J:double:blind:study
10885-3185:2009:Wider C:fgf:and:parkinson
10885-3185:2009:Weintraub D:validation:of:the
10885-3185:2009:Volkmann J:long:term:effects
10885-3185:2009:Van Nuenen B:mapping:preclinical:compensation
10885-3185:2009:Sage M:symptom:and:gait
10885-3185:2009:Ravina B:the:course:of
10885-3185:2009:Ravina B:a:longitudinal:program
10885-3185:2009:Rajput A:alpha:synuclein:polymorphisms
10885-3185:2009:Postuma R:idiopathic:rem:sleep
10885-3185:2009:Marras C:a:comparison:of
10885-3185:2009:Louis E:torpedoes:in:parkinson
10885-3185:2009:Klein C:hereditary:parkinsonism:parkinson
10885-3185:2009:Hauser R:double:blind:trial
10885-3185:2009:Fox S:serotonin:and:parkinson
10885-3185:2009:Evans A:impulsive:and:compulsive
10885-3185:2009:Elahi B:effect:of:transcranial
10885-3185:2009:Djarmati A:atp:a:variants
10885-3185:2009:Cobb S:gch:in:early
10885-3185:2009:Camicioli R:homocysteine:is:not
10885-3185:2008:Toth C:neuropathy:as:a
10885-3185:2008:Postuma R:manifestations:of:parkinson
10885-3185:2008:Olanow C:a:randomized:double
10885-3185:2008:Oates A:control:of:dynamic
10885-3185:2008:Munhoz R:the:g:s
10885-3185:2008:Mcnicoll C:huntington:cag:repeat
10885-3185:2008:Mcgeer P:glial:reactions:in
10885-3185:2008:Martin W:intact:presupplementary:motor
10885-3185:2008:Marras C:predictors:of:deterioration
10885-3185:2008:Lim S:do:dyskinesia:and
10885-3185:2008:Goetz C:movement:disorder:society
10885-3185:2008:Fox S:levodopa:related:motor
10885-3185:2008:Boileau I:elevated:serotonin:transporter
10885-3185:2007:Thomsen T:ipratropium:bromide:spray
10885-3185:2007:Strafella A:subdural:motor:cortex
10885-3185:2007:Rektorova I:functional:abnormalities:in
10885-3185:2007:Postuma R:is:there:seasonal
10885-3185:2007:Pickering R:a:meta:analysis
10885-3185:2007:Piboolnurak P:levodopa:response:in
10885-3185:2007:Miyasaki J:punding:prevalence:in
10885-3185:2007:Mendonca D:methylphenidate:improves:fatigue
10885-3185:2007:Marras C:antipsychotic:use:in
10885-3185:2007:Li J:interhemispheric:and:ipsilateral
10885-3185:2007:Landau A:proteasome:inhibitor:model
10885-3185:2007:Kishore A:unilateral:versus:bilateral
10885-3185:2007:Hauser R:ten:year:follow
10885-3185:2007:Hallett P:striatal:delta:opioid
10885-3185:2007:Goetz C:movement:disorder:society
10885-3185:2007:Emre M:clinical:diagnostic:criteria
10885-3185:2007:Djarmati A:rapid:and:reliable
10885-3185:2007:Camicioli R:magnetic:resonance:spectroscopic
10885-3185:2007:Berney A:mood:stability:during
10885-3185:2007:Almeida Q:dopaminergic:modulation:of
10885-3185:2006:Zadikoff C:homozygous:and:heterozygous
10885-3185:2006:Voon V:deep:brain:stimulation
10885-3185:2006:Volkmann J:basic:algorithms:for
10885-3185:2006:Visanji N:pharmacological:characterization:of
10885-3185:2006:Sherer T:crossroads:in:gdnf
10885-3185:2006:Rascol O:development:of:dyskinesias
10885-3185:2006:Morissette M:prevention:of:levodopa
10885-3185:2006:Mercado R:expectation:and:the
10885-3185:2006:Lang A:deep:brain:stimulation
10885-3185:2006:Koochesfahani K:oral:methylphenidate:fails
10885-3185:2006:Grimes D:translated:mutation:in
10885-3185:2006:Gomez Ramirez J:histamine:h:receptor
10885-3185:2006:Fox S:translation:of:nondopaminergic
10885-3185:2006:Deuschl G:deep:brain:stimulation
10885-3185:2006:Ardouin C:pathological:gambling:in
10885-3185:2005:Stacy M:identification:of:motor
10885-3185:2005:Proulx M:salivary:production:in
10885-3185:2005:Postuma R:does:severity:of
10885-3185:2005:Nataraj A:parkinson:s:disease
10885-3185:2005:Lun V:comparison:of:the
10885-3185:2005:Levesque J:gabaergic:interneurons:in
10885-3185:2005:Kishore A:normalization:of:voice
10885-3185:2005:Karamohamed S:absence:of:previously
10885-3185:2005:Camicioli R:apolipoprotein:e:and
10885-3185:2005:Brotchie J:nondopaminergic:mechanisms:in
10885-3185:2004:Toth C:anomalies:of:asymmetry
10885-3185:2004:Pereira L:neuronal:activity:in
10885-3185:2004:Olanow C:levodopa:in:the
10885-3185:2004:Marras C:quality:of:life
10885-3185:2004:Hedrich K:distribution:type:and
10885-3185:2004:Furtado S:profile:of:families
10885-3185:2003:Stefurak T:deep:brain:stimulation
10885-3185:2003:Inkster L:leg:muscle:strength
10885-3185:2003:Guttman M:burden:of:parkinsonism
10885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency
10885-3185:2003:Camicioli R:parkinson:s:disease
10885-3185:2003:Calon F:changes:of:gaba
10885-3185:2003:Belanger N:chronic:treatment:with
10885-3185:2003:Adkin A:fear:of:falling
10885-3185:2002:Rajput A:clinical:pathological:study
10885-3185:2002:Lozano A:microelectrode:recordings:in
10885-3185:2002:Lang A:deep:brain:stimulation
10885-3185:2002:Kim Y:combination:of:dopamine
10885-3185:2002:Grimes D:large:french:canadian
10885-3185:2002:Dostrovsky J:mechanisms:of:deep
10885-3185:2002:Almeida Q:bimanual:coordination:deficits
10885-3185:2001:Nieves A:acute:onset:dystonic
10885-3185:2001:Marras C:year:old:man
10885-3185:2001:Hutton J:transdermal:dopaminergic:d
10885-3185:2000:Tonolli I:lateral:leg:raising
10885-3185:2000:Mohr E:risperidone:in:the
10885-3185:2000:Dromey C:an:investigation:of
10885-3185:1998:Kumar R:pallidotomy:and:deep
10885-3185:1997:Rajput A:dopa:responsive:nonprogressive
10885-3185:1997:Prochazka A:measurement:of:rigidity
10885-3185:1996:Ye F:basal:ganglia:iron
10885-3185:1996:Blanchet P:dyskinesia:and:wearing
10885-3185:1995:Nahmias C:a:probe:for
10885-3185:1995:Lang A:hemiatrophy:juvenile:onset
10885-3185:1994:Mosewich R:pulmonary:embolism:an
10885-3185:1994:Hertzman C:a:case:control
10885-3185:1993:Guttman M:administration:of:the
10885-3185:1993:Gomez Mancilla B:effect:of:adding
10885-3185:1992:Pourcher E:ethosuximide:and:tremor
10885-3185:1992:Gomez Mancilla B:effect:of:ethosuximide
10885-3185:1990:Svenson L:geographic:distribution:of
10832-610X:2000:Robinson J:familial:hypokalemic:periodic
10767-3981:2012:Rascol O:a:proof:of
10767-3981:1995:Blanchet P:is:striatal:dopaminergic
10742-3098:2007:Sharma R:neural:stem:cell
10740-3194:1996:Ye F:estimation:of:brain
10738-3991:1999:Mackenzie G:issues:that:influence
10735-7044:1996:Miklyaeva E:hemiparkinson:analogue:rats
10735-1097:1989:Fujimura O:acute:effect:of
10735-1097:1988:Jones D:sequential:pulse:defibrillation
10735-1097:1987:Milstein S:comparison:of:the
10733-8619:1992:Guttman M:dopamine:receptors:in
10531-5565:2000:Schipper H:heme:oxygenase:role
10531-5565:1998:Mcgeer E:the:importance:of
10364-5134:2012:Marras C:dihydropyridine:calcium:channel
10364-5134:2012:Goldman S:solvent:exposures:and
10364-5134:2012:Goldman S:head:injury:alpha
10364-5134:2011:Voon V:impulse:control:disorders
10364-5134:2011:Cullen V:acid:glucosidase:mutants
10364-5134:2010:Weintraub D:amantadine:use:associated
10364-5134:2010:Toth C:levodopa:methylmalonic:acid
10364-5134:2010:Stocchi F:initiating:levodopa:carbidopa
10364-5134:2010:Rylander D:maladaptive:plasticity:of
10364-5134:2009:Gagnon J:mild:cognitive:impairment
10364-5134:2009:Ballanger B:stimulation:of:the
10364-5134:2008:Wenning G:multiple:system:atrophy
10364-5134:2008:Martin W:dihydrotetrabenazine:positron:emission
10364-5134:2007:Sossi V:dopamine:transporter:relation
10364-5134:2006:Samadi P:docosahexaenoic:acid:reduces
10364-5134:2006:Lang A:randomized:controlled:trial
10364-5134:2006:Galpern W:interface:between:tauopathies
10364-5134:2004:Tong J:brain:dopamine:stimulated
10364-5134:2003:Whone A:slower:progression:of
10364-5134:2003:Olanow C:a:double:blind
10364-5134:2003:Mcgeer P:presence:of:reactive
10364-5134:2003:Hutchison W:pallidal:neuronal:activity
10364-5134:2003:Hague S:early:onset:parkinson
10364-5134:2002:Furukawa Y:brain:proteasomal:function
10364-5134:2001:Fukuda M:functional:correlates:of
10364-5134:2001:De La Fuente Fernandez R:biochemical:variations:in
10364-5134:2000:Lozano A:neuronal:recordings:in
10364-5134:2000:Lee C:in:vivo:positron
10364-5134:2000:Lang A:surgery:for:levodopa
10364-5134:2000:Huynh D:parkin:is:associated
10364-5134:2000:Filion M:physiologic:basis:of
10364-5134:2000:Calon F:molecular:basis:of
10364-5134:1997:Vingerhoets F:which:clinical:sign
10364-5134:1994:Vingerhoets F:positron:emission:tomographic
10364-5134:1994:Vingerhoets F:longitudinal:fluorodopa:positron
10364-5134:1994:Uitti R:parkinsonism:induced:by
10364-5134:1993:Snow B:human:positron:emission
10364-5134:1992:Calne D:criteria:for:diagnosing
10364-5134:1991:Bhatt M:positron:emission:tomography
10364-5134:1989:Wolters E:positron:emission:tomography
10364-3190:1996:Berry M:aromatic:l:amino
10364-3190:1994:Scarr E:the:effects:of
10363-6135:2006:Dolinsky V:role:of:amp
10362-5664:1995:Lang A:remoxipride:in:parkinson
10362-5664:1991:Gomez Mancilla B:effect:of:clonidine
10362-5664:1989:Wolters E:clozapine:an:antipsychotic
10362-5664:1987:Lang A:restless:legs:syndrome
10361-9230:1998:Loeffler D:altered:guanosine:and
10361-9230:1991:Jolicoeur F:hypokinesia:rigidity:and
10360-4012:1990:Peppard R:cortical:glucose:metabolism
10340-6717:2008:Destefano A:replication:of:association
10340-5354:2008:Lozano A:deep:brain:stimulation
10340-0131:2004:Beuter A:effect:of:chronic
10317-1671:2013:Zeiler F:subthalamic:nucleus:deep
10317-1671:2013:Akram S:parkinson:s:disease
10317-1671:2012:Salat Foix D:increased:intestinal:permeability
10317-1671:2012:Nelson A:dopamine:alters:tactile
10317-1671:2012:Elahi B:n:methyl:d
10317-1671:2011:Noreau A:glucocerebrosidase:mutations:in
10317-1671:2011:Auclair Ouellet N:transient:executive:dysfunction
10317-1671:2010:Wiltshire K:corpus:callosum:and
10317-1671:2010:Parent M:substantia:nigra:and
10317-1671:2010:Bharmal A:outcomes:of:patients
10317-1671:2008:Zadikoff C:pergolide:associated:cardiac
10317-1671:2008:Mendonca D:tasks:of:attention
10317-1671:2007:Yiannakoulias N:parkinson:s:disease
10317-1671:2007:Grimes D:lrrk:screening:in
10317-1671:2007:Dupre N:lrrk:is:not
10317-1671:2007:De Bie R:clinical:practice:regarding
10317-1671:2007:Camicioli R:clinical:trials:in
10317-1671:2007:Acharya H:axial:signs:and
10317-1671:2006:Zadikoff C:cardiac:valvulopathy:associated
10317-1671:2006:Scozzafava J:valvular:heart:disease
10317-1671:2005:Lang A:progress:in:clinical
10317-1671:2005:Han F:neurofilament:m:gene
10317-1671:2003:Martin W:treatment:of:parkinson
10317-1671:2003:Blanchet P:the:fluctuating:parkinsonian
10317-1671:2002:Parent A:jules:bernard:luys
10317-1671:2002:Jenkins M:hemiparkinsonism:somatic:hemiatrophy
10317-1671:2002:Guttman M:parkinsonism:in:ontario
10317-1671:2000:Honey C:a:prospective:randomized
10317-1671:1999:Stoessl A:etiology:of:parkinson
10317-1671:1999:Stoessl A:differential:diagnosis:of
10317-1671:1999:Rivest J:comt:inhibitors:in
10317-1671:1999:Honey C:new:developments:in
10317-1671:1999:Hobson D:ropinirole:and:pramipexole
10317-1671:1999:Guttman M:parkinson:s:disease
10317-1671:1999:Grimes D:treatment:of:early
10317-1671:1999:Blanchet P:rationale:for:use
10317-1671:1998:Martin W:increased:basal:ganglia
10317-1671:1998:Galvez Jimenez N:pallidal:stimulation:in
10317-1671:1997:Strafella A:pallidotomy:increases:cortical
10317-1671:1997:Paquet N:responses:to:dynamic
10317-1671:1997:Mehta V:neural:transplantation:in
10317-1671:1996:Galvez Jimenez N:perioperative:problems:in
10317-1671:1996:Charbonneau D:impaired:incentive:learning
10317-1671:1996:Blanchet P:risk:factors:for
10317-1671:1995:Chaturvedi S:environmental:exposures:in
10317-1671:1993:Borrett D:neural:networks:and
10317-1671:1992:Vezina P:deprenyl:in:parkinson
10317-1671:1992:Tatton W:interactions:between:mptp
10317-1671:1992:Stoessl A:prevention:and:management
10317-1671:1992:Snow B:positron:emission:tomography
10317-1671:1992:Robertson H:synergistic:interactions:of
10317-1671:1992:Rajput A:frequency:and:cause
10317-1671:1992:Mohr E:neuropsychological:and:glucose
10317-1671:1992:King D:the:place:of
10317-1671:1992:Eisen A:amyotrophic:lateral:sclerosis
10317-1671:1992:Beuter A:the:organization:of
10317-1671:1991:Semchuk K:parkinson:s:disease
10317-1671:1991:Rajput A:accuracy:of:clinical
10317-1671:1991:Poirier J:environment:genetics:and
10317-1671:1991:Kofman O:deprenyl:protective:vs
10317-1671:1991:Furtado J:mptp:induced:neurotoxicity
10317-1671:1990:Ross R:drug:induced:parkinsonism
10317-1671:1990:Lang A:cqa:in:parkinson
10317-1671:1989:Uitti R:regional:metal:concentrations
10317-1671:1989:Guttman M:pet:studies:of
10317-1671:1988:Taylor A:idiopathic:parkinson:s
10317-1671:1988:Riopelle R:adrenal:medulla:autografts
10317-1671:1988:Hurwitz T:treatment:of:dopaminomimetic
10317-1671:1988:Calne D:late:progression:of
10317-1671:1987:Libman I:a:comparison:of
10317-1671:1987:Kimura D:attentional:and:perseverative
10317-1671:1987:Calne S:familial:parkinson:s
10317-1671:1987:Barbeau A:ecogenetics:of:parkinson
10317-1671:1986:Rajput A:early:onset:parkinson
10315-162X:1998:Uhrin Z:rheumatoid:like:deformities
10306-9877:1992:Rathbone M:purinergic:stimulation:of
10306-9877:1992:Parkinson D:concussion:is:completely
10306-5251:1990:Campbell N:sinemet:ferrous:sulphate
10306-4522:2013:Lee D:reaching:to:proprioceptively
10306-4522:2011:Wichmann T:pathological:basal:ganglia
10306-4522:2011:Paquette C:walking:in:circles
10306-4522:2009:Palmer S:levodopa:sensitive:dynamic
10306-4522:2009:Mongeon D:impact:of:parkinson
10306-4522:2008:Lai Y:neurotoxic:lesions:at
10306-4522:2007:Lewis M:task:specific:influences
10306-4522:2006:Rasouli G:fractal:characteristics:of
10306-4522:2005:Rafuse V:neuroprotective:properties:of
10306-4522:2005:Almeida Q:an:evaluation:of
10306-4522:2002:Kiss Z:neuronal:response:to
10306-4522:2001:Ross B:elevated:activity:of
10306-4522:2000:Lu X:naloxone:prevents:microglia
10306-4522:1999:Flores G:expression:of:dopamine
10306-4522:1998:Ross B:low:activity:of
10306-4522:1997:Tatton N:in:situ:detection
10306-4522:1997:Goulet M:continuous:or:pulsatile
10306-4522:1996:Trepanier G:immunocytochemical:localization:of
10306-4522:1991:Moriizumi T:separate:neuronal:populations
10306-4522:1990:Pare D:neuronal:basis:of
10306-3623:1994:Yu P:pharmacological:and:clinical
10306-3623:1994:Parkinson F:propentofylline:a:nucleoside
10304-3991:1981:Egerton R:the:range:of
10304-3959:1999:Radhakrishnan V:a:comparison:of
10304-3959:1992:Cott A:long:term:efficacy
10304-3940:2008:Camicioli R:early:untreated:parkinson
10304-3940:2004:Groen J:genetic:association:study
10304-3940:2004:Camicioli R:posterior:cingulate:metabolic
10304-3940:2002:Mcgeer P:association:of:interleukin
10304-3940:2000:Choi H:the:effects:of
10304-3940:1999:Miranda A:quinolinic:acid:lesion
10304-3940:1996:Yasuhara O:midkine:like:immunoreactivity
10304-3940:1996:Anderson C:ability:of:nitrobenzylthioinosine
10304-3940:1993:Gagnon C:chronic:cy:treatment
10304-3940:1990:Yamada T:complement:activated:oligodendroglia
10304-3940:1989:Bedard P:effect:of:d
10304-3940:1988:Wolters E:a:new:device
10304-3940:1988:Perry T:tetrahydroisoquinoline:lacks:dopaminergic
10304-3940:1987:Perry T:phenylpyridine:and:three
10304-3940:1987:Perry T:exposure:to:cigarette
10304-3940:1987:Hannah R:the:effect:of
10304-3940:1986:Perry T:paraquat:and:two
10303-8467:2008:Fenney A:short:term:variability
10301-0082:1994:Berry M:possible:mechanisms:of
10300-9564:2000:De La Fuente Fernandez R:evidence:for:impaired
10300-8177:1992:Kalra J:serum:antioxidant:enzyme
10300-8177:1992:Kalra J:oxygen:free:radical
10278-5846:2000:Goulet M:regulation:by:chronic
10278-5846:1995:Gagnon C:effect:of:adding
10278-5846:1988:Pisa M:regional:specialization:of
10278-5846:1988:Hassan M:dopamine:receptors:in
10278-5846:1988:Grimes J:prevention:of:progression
10278-2626:2005:Bertram C:the:effect:of
10278-2626:2000:Trepanier L:neuropsychological:outcome:of
10278-2626:2000:Godbout L:defective:representation:of
10278-2626:1999:Bedard M:acute:and:long
10278-2626:1998:Knoke D:the:differential:effects
10278-2626:1997:Doyon J:role:of:the
10278-2626:1995:Taylor A:the:neuropsychology:of
10278-2626:1995:Shinotoh H:the:use:of
10278-2626:1990:Taylor A:memory:and:learning
10278-2626:1989:Freedman M:spatial:and:visual
10277-9536:1995:Emard J:neurodegenerative:diseases:and
10271-678X:2004:Sossi V:changes:of:dopamine
10271-678X:2003:Sossi V:effect:of:dopamine
10271-678X:2002:Sossi V:increase:in:dopamine
10271-678X:2001:De La Fuente Fernandez R:apomorphine:induced:changes
10271-3586:1990:Hertzman C:parkinson:s:disease
10271-0749:1996:Sandor P:remoxipride:in:the
10270-6474:1992:Paul M:d:like:and
10270-6474:1988:Lenz F:single:unit:analysis
10269-8811:2009:Zuardi A:cannabidiol:for:the
10269-2155:2002:Meshack R:a:randomized:controlled
10197-4580:1999:Schwab C:on:the:survival
10197-4580:1998:Schwab C:tubulin:immunopositive:structures
10197-0186:2006:Julien C:postmortem:brain:fatty
10197-0186:1999:Reader T:effects:of:denervation
10197-0186:1999:Calon F:chronic:d:and
10197-0186:1992:Calne D:the:nature:of
10196-9781:2007:Castellano J:mif:and:its
10195-6663:1988:Weingarten H:ventromedial:hypothalamic:lesions
10171-2004:2012:Yeomans J:muscarinic:receptors:in
10169-409X:2000:Shoichet M:cell:delivery:to
10169-328X:1999:Anderson C:distribution:of:mrna

Manipulations en shell (Unix/Dilib)

HfdCat /applis/lorexplor/Wicri/Amerique/Canada/explor/ParkinsonCanada.storage/ParkisonCanadaV1/Data/Main/Curation/DoubleIdat.i.hfd| SxmlCut idx/l | grep ...
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022